The in-vitro activity of azlocillin: a community hospital study of 1900 clinical isolates.
The in-vitro activity of azlocillin was evaluated against 1900 fresh clinical isolates from a 320-bed community hospital. Azlocillin inhibited over 90% of Pseudomonas aeruginosa isolates at less than or equal to 16 mg/l; it was four-fold more active than ticarcillin and 8- to 16-fold more active than carbenicillin. Against members of the Enterobacteriaceae azlocillin was less active than piperacillin but still inhibited over 90% of Klebsiella, Serratia and Proteus mirabilis at achievable blood levels (less than or equal to 64 mg/l). It was the most active agent against enterococci inhibiting 80% at less than or equal to 1 mg/l. Azlocillin will be a useful addition to the antibiotic formulary of the community hospital because of its exceptional anti-pseudomonal activity.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001390:Azlocillin; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology; D004755:Enterobacteriaceae / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D010406:Penicillins / Q000494:pharmacology*; D011549:Pseudomonas / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D010406:Penicillins; D001390:Azlocillin